NIST March-In Framework: The Controversial Path to Lower Prescription Drug Costs

The U.S. Department of Commerce National Institute of Standards and Technology (NIST)’s proposed march-in framework under the Bayh-Dole Act has been a focal point of attention lately in the legal and pharmaceutical spaces. The framework, which pertains to when the government can seize patents, is seen as a radical change that could pave the way to lower prescription drug costs. It has, however, been met with diverse viewpoints and heated commentary within the industry.

While this seems like a fresh new approach on the surface, a closer examination reveals that the language at its core is identical to a failed 2021 notice of proposed rulemaking, as noted by Attorney Kelly Morron. Though this might bring a sense of déjà vu for some, the implications of the proposal cannot be understated and it continues to spark rigorous debates and discussions within legal circles.

Considering the critical intersection of statutory analysis, policy, and federally funded innovation, the NIST’s march-in framework generates more than a ripple in the water. The deadline for comments on this proposal closed on February 6th and the industry now awaits the next development in this ongoing narrative.

To delve deeper into the complexities of the proposed framework and its implications, you can read the in-depth legal analysis by Kelly Morron.